AHR and breast cancer: Kang et al found decreased risk of recurrence among post-menopausal women consuming >42.3mg isoflavones in a cohort of breast cancer patients, all of whom were on tamoxifen or aromatase inhibitors, AHR 0.67 (0.54-0.85) [106].